Drugs / Persantin®
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02259998 Comparator | Oct → Dec 2001 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Persantin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02259998 ↗ |
| Route | Oral | “75 mg p.o. (Present and Proposed Formulation in France)” NCT02259998 ↗ |